Biomarin Pharmaceutical Inc (BMRN)
87.35
-1.28
(-1.44%)
USD |
NASDAQ |
Mar 28, 16:00
87.35
0.00 (0.00%)
After-Hours: 20:00
Biomarin Pharmaceutical Enterprise Value: 16.74B for March 27, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 27, 2024 | 16.74B |
March 26, 2024 | 16.57B |
March 25, 2024 | 16.34B |
March 22, 2024 | 16.08B |
March 21, 2024 | 15.88B |
March 20, 2024 | 16.01B |
March 19, 2024 | 16.10B |
March 18, 2024 | 15.83B |
March 15, 2024 | 15.84B |
March 14, 2024 | 15.94B |
March 13, 2024 | 16.01B |
March 12, 2024 | 16.08B |
March 11, 2024 | 16.24B |
March 08, 2024 | 16.23B |
March 07, 2024 | 16.22B |
March 06, 2024 | 16.38B |
March 05, 2024 | 16.24B |
March 04, 2024 | 16.56B |
March 01, 2024 | 16.45B |
February 29, 2024 | 16.29B |
February 28, 2024 | 16.69B |
February 27, 2024 | 17.12B |
February 26, 2024 | 17.01B |
February 23, 2024 | 17.23B |
February 22, 2024 | 16.99B |
Date | Value |
---|---|
February 21, 2024 | 16.72B |
February 20, 2024 | 16.74B |
February 16, 2024 | 16.76B |
February 15, 2024 | 16.67B |
February 14, 2024 | 16.23B |
February 13, 2024 | 16.26B |
February 12, 2024 | 16.64B |
February 09, 2024 | 16.70B |
February 08, 2024 | 16.64B |
February 07, 2024 | 16.92B |
February 06, 2024 | 16.95B |
February 05, 2024 | 16.56B |
February 02, 2024 | 16.63B |
February 01, 2024 | 16.75B |
January 31, 2024 | 16.62B |
January 30, 2024 | 16.92B |
January 29, 2024 | 17.32B |
January 26, 2024 | 17.15B |
January 25, 2024 | 17.22B |
January 24, 2024 | 17.42B |
January 23, 2024 | 17.56B |
January 22, 2024 | 17.75B |
January 19, 2024 | 17.41B |
January 18, 2024 | 17.46B |
January 17, 2024 | 17.63B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
11.67B
Minimum
Oct 02 2019
23.80B
Maximum
Jul 20 2020
15.94B
Average
15.63B
Median
Jan 29 2020
Enterprise Value Benchmarks
Eli Lilly and Co | 762.26B |
Pfizer Inc | 215.30B |
Regeneron Pharmaceuticals Inc | 97.27B |
Vertex Pharmaceuticals Inc | 96.63B |
Moderna Inc | 33.75B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 20.38M |
Revenue (Quarterly) | 646.21M |
Total Expenses (Quarterly) | 631.93M |
EPS Diluted (Quarterly) | 0.11 |
Gross Profit Margin (Quarterly) | 79.03% |
Profit Margin (Quarterly) | 3.15% |
Earnings Yield | 1.01% |
Operating Earnings Yield | 0.94% |
Normalized Earnings Yield | 1.007 |